Inhibikase Therapeutics, Inc.
IKT · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $145,883 | $175,519 | $196,086 | $225,428 |
| - Cash | $38,270 | $77,743 | $73,441 | $56,491 |
| + Debt | $0 | $38 | $75 | $111 |
| Enterprise Value | $107,613 | $97,814 | $122,720 | $169,048 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | -$24 | -$24 | -$13 | -$7 |
| % Margin | – | – | – | – |
| EBITDA | -$11,907 | -$11,167 | -$15,750 | -$12,126 |
| % Margin | – | – | – | – |
| Net Income | -$11,930 | -$9,916 | -$13,679 | -$12,133 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.133 | -0.11 | -0.15 | -0.17 |
| % Growth | -20.5% | 26.7% | 11.8% | – |
| Operating Cash Flow | -$10,593 | -$5,574 | -$4,104 | -$5,346 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$10,593 | -$5,574 | -$4,104 | -$5,346 |